|To: Ken W who wrote (20095)||11/6/2006 11:46:50 AM|
|From: Galirayo||Respond to of 23958|
|LOL .. don't loose "sight" of the Big Picture.|
Italian Undersecretary of State Lauds Collaboration
TORONTO--(MARKET WIRE)--Oct 23, 2006 -- On October 20, 2006, Generex Biotechnology Corporation (NASDAQ:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, together with University Campus Bio-Medico of Rome, Italy, hosted a symposium as an adjunct to the Canadian Diabetes Association Professional Conference and Annual Meetings in Toronto, Canada.
The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at generex.com